Lightlake Therapeutics (LLTP) 7.4500 $LLTP
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
PR Newswire - Wed Jun 03, 8:34AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose. A rolling submission allows completed portions of the NDA to be submitted and reviewed by the FDA on an ongoing basis.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study
PR Newswire - Wed Apr 22, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, successfully completed a clinical study of intranasal naloxone.
Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
PR Newswire Europe - Mon Mar 09, 8:01AM CDT
- Lightlake invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation.
5 Live Investor Webcasts from Aflac and Life Sciences Companies: March 5 at VirtualInvestorConferences.com
PR Newswire - Tue Mar 03, 7:30AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
RDHL: 18.46 (+0.11), ONVO: 3.82 (+0.26)
Lightlake Therapeutics Inc. Announces Fast Track Designation From The United States Food And Drug Administration For Intranasal Naloxone Treatment To Reverse Opioid Overdose
PR Newswire - Tue Feb 17, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake's partner for treating opioid overdose with intranasal naloxone, has received Fast Track designation by the United States Food and Drug Administration ("FDA" .
Lightlake Therapeutics Inc. Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs
PR Newswire - Mon Feb 09, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Arvind Agrawal has joined Lightlake as Executive Vice President, Medical Affairs, effective January 2015.
LightLake Therapeutics teams up with Adapt Pharma
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 9:26AM CST
Lightlake Therapeutics Inc. Announces Licensing Deal With Adapt Pharma Limited Subsidiary
PR Newswire - Tue Dec 16, 7:30AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has entered into a license agreement with Adapt Pharma Operations Limited ("Adapt" , a wholly owned subsidiary of Adapt Pharma Limited, an Ireland-based pharmaceutical company ("Adapt Pharma" . Pursuant to the agreement Adapt has received from Lightlake a global license to develop and commercialize Lightlake's intranasal naloxone opioid overdose reversal treatment. In exchange for licensing its treatment to Adapt, Lightlake could receive potential development and sales milestone payments of more than $55 million, plus up to double-digit royalties.
Lightlake Therapeutics Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA)
PR Newswire - Thu Dec 04, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Lightlake has begun a trial designed to evaluate its intranasal naloxone application for opioid overdose.
Drug Addiction - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/44hwmz/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Gilead Sciences, Inc. - Aphios Corporation - Teva Pharmaceutical Industries Limited - Addex Therapeutics Ltd - Biotie Therapies Corp. - Camurus AB - Curemark, LLC - Rottapharm SpA - Omeros Corporation - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - D&A Pharma SAS - Embera NeuroTherapeutics, Inc. - Lightlake Therapeutics Inc. - SK Biopharmaceuticals Co., Ltd. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/44..._addiction
GILD: 113.74 (+0.38), TEVA: 61.38 (-0.75), OMER: 17.33 (+0.29)
Lightlake Therapeutics Inc. Announces Closing Of Investments In Two Products
PR Newswire - Thu Oct 02, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has closed on investments totaling $1,000,000. The investments were made by an investor in exchange for interests in two different Lightlake products.
Global Binge Eating Disorder Therapeutics Pipeline Review, H2 2014 Report - 5 Companies & 5 Drug Profiles
M2 - Wed Sep 10, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6jpp4g/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Teva Pharmaceutical Industries Limited - Shire Plc - Omeros Corporation - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. Drug Profiles - armodafinil - lisdexamfetamine dimesylate - LT-12 - OMS-527 - Small Molecule Targeting Orexin 1 For more information visit http://www.researchandmarkets.com/research/6j...nge_eating
SHPG: 250.34 (+7.35), TEVA: 61.38 (-0.75), OMER: 17.33 (+0.29)
Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
PR Newswire - Wed Jul 23, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND" with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to fund a second study with respect to Lightlake's nasal spray. Lightlake, in collaboration with NIDA, previously commenced a clinical trial with respect to its nasal spray in September 2013.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
PR Newswire - Wed Jun 03, 8:34AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose. A rolling submission allows completed portions of the NDA to be submitted and reviewed by the FDA on an ongoing basis. Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study
PR Newswire - Wed Apr 22, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, successfully completed a clinical study of intranasal naloxone. Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
PR Newswire Europe - Mon Mar 09, 8:01AM CDT
- Lightlake invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation.
5 Live Investor Webcasts from Aflac and Life Sciences Companies: March 5 at VirtualInvestorConferences.com
PR Newswire - Tue Mar 03, 7:30AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
RDHL: 18.46 (+0.11), ONVO: 3.82 (+0.26)
Lightlake Therapeutics Inc. Announces Fast Track Designation From The United States Food And Drug Administration For Intranasal Naloxone Treatment To Reverse Opioid Overdose
PR Newswire - Tue Feb 17, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake's partner for treating opioid overdose with intranasal naloxone, has received Fast Track designation by the United States Food and Drug Administration ("FDA" . Lightlake Therapeutics Inc. Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs
PR Newswire - Mon Feb 09, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Arvind Agrawal has joined Lightlake as Executive Vice President, Medical Affairs, effective January 2015. LightLake Therapeutics teams up with Adapt Pharma
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 9:26AM CST
Lightlake Therapeutics Inc. Announces Licensing Deal With Adapt Pharma Limited Subsidiary
PR Newswire - Tue Dec 16, 7:30AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has entered into a license agreement with Adapt Pharma Operations Limited ("Adapt" , a wholly owned subsidiary of Adapt Pharma Limited, an Ireland-based pharmaceutical company ("Adapt Pharma" . Pursuant to the agreement Adapt has received from Lightlake a global license to develop and commercialize Lightlake's intranasal naloxone opioid overdose reversal treatment. In exchange for licensing its treatment to Adapt, Lightlake could receive potential development and sales milestone payments of more than $55 million, plus up to double-digit royalties. Lightlake Therapeutics Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA)
PR Newswire - Thu Dec 04, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Lightlake has begun a trial designed to evaluate its intranasal naloxone application for opioid overdose. Drug Addiction - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/44hwmz/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Gilead Sciences, Inc. - Aphios Corporation - Teva Pharmaceutical Industries Limited - Addex Therapeutics Ltd - Biotie Therapies Corp. - Camurus AB - Curemark, LLC - Rottapharm SpA - Omeros Corporation - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - D&A Pharma SAS - Embera NeuroTherapeutics, Inc. - Lightlake Therapeutics Inc. - SK Biopharmaceuticals Co., Ltd. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/44..._addiction
GILD: 113.74 (+0.38), TEVA: 61.38 (-0.75), OMER: 17.33 (+0.29)
Lightlake Therapeutics Inc. Announces Closing Of Investments In Two Products
PR Newswire - Thu Oct 02, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has closed on investments totaling $1,000,000. The investments were made by an investor in exchange for interests in two different Lightlake products. Global Binge Eating Disorder Therapeutics Pipeline Review, H2 2014 Report - 5 Companies & 5 Drug Profiles
M2 - Wed Sep 10, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6jpp4g/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Teva Pharmaceutical Industries Limited - Shire Plc - Omeros Corporation - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. Drug Profiles - armodafinil - lisdexamfetamine dimesylate - LT-12 - OMS-527 - Small Molecule Targeting Orexin 1 For more information visit http://www.researchandmarkets.com/research/6j...nge_eating
SHPG: 250.34 (+7.35), TEVA: 61.38 (-0.75), OMER: 17.33 (+0.29)
Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
PR Newswire - Wed Jul 23, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake"
(OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND" with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to fund a second study with respect to Lightlake's nasal spray. Lightlake, in collaboration with NIDA, previously commenced a clinical trial with respect to its nasal spray in September 2013. 
